Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Diabetic patients are at higher risk of liver dysfunction compared with the normal population. Thus, using hypoglycemic agents to improve liver efficiency is important in these patients. Sodium-glucose cotransporters-2 inhibitors (SGLT2i) are newly developed antidiabetic drugs with potent glucose-lo...

Descripción completa

Detalles Bibliográficos

Autores principales:	Habib Yaribeygi, Mina Maleki, Tannaz Jamialahamdi, Seyed Adel Moallem, Amirhossein Sahebkar
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund 2023-04-01
Colección:	EXCLI Journal : Experimental and Clinical Sciences
Materias:	diabetes mellitus sodium-glucose cotransporter-2 inhibitors liver non-alcoholic fatty liver disorders fibrosis hepatocellular carcinoma cirrhosis
Acceso en línea:	https://www.excli.de/index.php/excli/article/view/6022
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!